ARAF: Serine/threonine-protein kinase A-Raf
Involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ARAF, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| LY-3009120 | Phase 1 | Eli Lilly | Small molecule | InhibitorSerine/threonine-protein kinase A-Raf inhibitor | 0 |
- Cancer0.56
- Noonan syndrome0.54
- Hypertrophic cardiomyopathy0.54
- Costello syndrome0.54
- Low grade glioma0.50
- Lymphatic malformation 120.42
- Glioma0.38
- Colorectal adenocarcinoma0.28
- Lung adenocarcinoma0.24
- Small cell lung carcinoma0.22
- Melanoma0.21
- Lung carcinoma0.20
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1169596, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10398, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets